Daiichi Sankyo Antibody-Pyrrolobenzodiazepine Derivative Conjugate Cancer Therapy Patent
Summary
The USPTO granted patent US12606634B2 to Daiichi Sankyo Company, Limited on April 21, 2026, covering a novel antibody-pyrrolobenzodiazepine derivative conjugate that binds claudin-6 (CLDN6) and claudin-9 (CLDN9) proteins, with applications in cancer therapy. The patent contains 17 claims under CPC classifications A61K 47/6803, A61P 35/00, C07D 487/04, and C07K 16/30.
What changed
The USPTO issued a new patent grant to Daiichi Sankyo Company, Limited for a novel antibody-pyrrolobenzodiazepine derivative conjugate and associated CLDN6/CLDN9 antibodies with applications in cancer treatment.
For competitors in the oncology biopharmaceutical space, this patent establishes intellectual property protection around a specific molecular target (claudin-6 and claudin-9) that may affect research and development strategies for antibody-drug conjugates targeting these proteins.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9
Grant US12606634B2 Kind: B2 Apr 21, 2026
Assignee
DAIICHI SANKYO COMPANY, LIMITED
Inventors
Narihiro Toda, Yusuke Ota, Fuminao Doi, Masaki Meguro, Ichiro Hayakawa, Shinji Ashida, Takeshi Masuda, Takashi Nakada, Mitsuhiro Iwamoto, Naoya Harada, Tomoko Terauchi, Daisuke Okajima, Kensuke Nakamura, Hiroaki Uchida, Hirofumi Hamada
Abstract
The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.
CPC Classifications
A61K 47/6803 A61P 35/00 C07D 487/04 C07K 16/30
Filing Date
2024-04-08
Application No.
18629444
Claims
17
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.